Xaira Therapeutics, a new biotech startup focusing on AI-driven drug discovery, has successfully launched with over $1 billion in funding. The company, led by former Stanford president Marc Tessier-Lavigne, aims to leverage artificial intelligence to develop new therapeutic approaches that are difficult to achieve with conventional methods. The funding was jointly incubated by Arch Venture Partners and Foresite Labs, with significant contributions from other major investors. Tessier-Lavigne, who recently left Stanford following a controversial exit related to an investigation, is joined by high-profile figures in biotech, including Scott Gottlieb and Alex Gorsky, signaling a strong endorsement of Xaira's potential in the biotech industry. The company is built on foundational technology from David Baker.